Skip to main content
Erschienen in: Tumor Biology 9/2016

23.07.2016 | Original Article

Overexpression of MYCN promotes proliferation of non-small cell lung cancer

verfasst von: Kun Liu, Shuo Wang, Yifei Liu, Jun Gu, Shudong Gu, Zhen Xu, Rui Zhang, Zhiwen Wang, Huaci Ma, Yingying Chen, Lili Ji

Erschienen in: Tumor Biology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) is an oncogene that is known amplified and overexpressed in different human malignancies including small cell lung cancer. However, the role of MYCN in non-small cell lung cancer (NSCLC) development remains elusive. In the present study, Western blot and immunohistochemistry assays demonstrated that MYCN was overexpressed in NSCLC tumor tissues and cell lines. In addition, immunohistochemistry analysis revealed that upregulation of MYCN expression was positively correlated with a more invasive tumor phenotype and poor prognosis. In vitro studies using serum starvation-refeeding experiment and MYCN-siRNA transfection assay demonstrated that MYCN expression promoted proliferation of NSCLC cells, while MYCN knockdown led to decreased cell growth resulted from growth arrest of cell cycle at G0/G1 phase. Furthermore, upregulation and knockdown of sex-determining region Y-box 2 (SRY) (SOX2), which was a well-known oncogene, confirmed that MYCN might be a downstream gene of the transcription factor SOX2. Collectively, our finding suggested that MYCN might contribute to the progression of NSCLC by enhancing cell proliferation, and that targeting MYCN might provide beneficial effects for the clinical therapy of NSCLC.
Literatur
1.
2.
3.
Zurück zum Zitat Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801.PubMed Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801.PubMed
4.
Zurück zum Zitat Chen G, Yi XH. Pathology and genetics of disease and tumours of the lung, pleura in China. Zhonghua Bing Li Xue Za Zhi. 2005;34(8):490–3.PubMed Chen G, Yi XH. Pathology and genetics of disease and tumours of the lung, pleura in China. Zhonghua Bing Li Xue Za Zhi. 2005;34(8):490–3.PubMed
5.
Zurück zum Zitat Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52(2):207–12.CrossRefPubMed Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52(2):207–12.CrossRefPubMed
6.
Zurück zum Zitat Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653–99.CrossRefPubMed Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653–99.CrossRefPubMed
7.
8.
Zurück zum Zitat Nau MM, Brooks Jr BJ, Carney DN, Gazdar AF, Battey JF, et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A. 1986;83(4):1092–6.CrossRefPubMedPubMedCentral Nau MM, Brooks Jr BJ, Carney DN, Gazdar AF, Battey JF, et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A. 1986;83(4):1092–6.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Engelen E, Akinci U, Bryne JC, Hou J, Gontan C, et al. Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. Nat Genet. 2011;43(6):607–11.CrossRefPubMed Engelen E, Akinci U, Bryne JC, Hou J, Gontan C, et al. Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. Nat Genet. 2011;43(6):607–11.CrossRefPubMed
10.
Zurück zum Zitat Liu K, Lin B, Zhao M, Yang X, Chen M, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013;25(5):1264–71.CrossRefPubMed Liu K, Lin B, Zhao M, Yang X, Chen M, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013;25(5):1264–71.CrossRefPubMed
11.
Zurück zum Zitat Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. SOX2 is an amplified lineage-survual oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–42.CrossRefPubMedPubMedCentral Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. SOX2 is an amplified lineage-survual oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–42.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung cell carcinomas. PLoS One. 2010;5(1):e8960.CrossRefPubMedPubMedCentral Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung cell carcinomas. PLoS One. 2010;5(1):e8960.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Rudin CM1, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–6.CrossRefPubMedPubMedCentral Rudin CM1, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–6.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wan C, Hou S, Ni R, Lv L, Ding Z, et al. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene. 2015;34(2):237–45.CrossRefPubMed Wan C, Hou S, Ni R, Lv L, Ding Z, et al. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene. 2015;34(2):237–45.CrossRefPubMed
15.
Zurück zum Zitat Wang Y, Liu F, Mao F, Hang Q, Huang X, et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J Biol Chem. 2013;288(13):9028–34.CrossRefPubMedPubMedCentral Wang Y, Liu F, Mao F, Hang Q, Huang X, et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J Biol Chem. 2013;288(13):9028–34.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5):e63404.CrossRefPubMedPubMedCentral Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5):e63404.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wang Y, Wang Y, Xiang J, Ji F, Deng Y, et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 2014;343(1):6–13.CrossRefPubMed Wang Y, Wang Y, Xiang J, Ji F, Deng Y, et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 2014;343(1):6–13.CrossRefPubMed
18.
Zurück zum Zitat Wang Y, Yang S, Ni Q, He S, Zhao Y, et al. Overexpression of forkhead box J2 can decrease the migration of breast cancer cells. J Cell Biochem. 2012;113(8):2729–37.CrossRefPubMed Wang Y, Yang S, Ni Q, He S, Zhao Y, et al. Overexpression of forkhead box J2 can decrease the migration of breast cancer cells. J Cell Biochem. 2012;113(8):2729–37.CrossRefPubMed
19.
Zurück zum Zitat Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefPubMed Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefPubMed
20.
Zurück zum Zitat Bell E, Chen L, Liu T, Marshall GM, Lunec J, et al. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):144–57.CrossRefPubMed Bell E, Chen L, Liu T, Marshall GM, Lunec J, et al. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):144–57.CrossRefPubMed
21.
Zurück zum Zitat Woo CW, Tan F, Cassano H, Lee J, Lee KC, et al. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer. 2008;50(2):208–12.CrossRefPubMed Woo CW, Tan F, Cassano H, Lee J, Lee KC, et al. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer. 2008;50(2):208–12.CrossRefPubMed
22.
Zurück zum Zitat Feng C, Wang T, Tang R, Wang J, Long H, et al. Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int. 2010;26(12):1185–91.CrossRefPubMed Feng C, Wang T, Tang R, Wang J, Long H, et al. Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int. 2010;26(12):1185–91.CrossRefPubMed
23.
Zurück zum Zitat Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, et al. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol. 2007;30(5):1189–96.PubMed Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, et al. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol. 2007;30(5):1189–96.PubMed
24.
Zurück zum Zitat Malynn BA, de Alboran IM, O’Hagan RC, Bronson R, Davidson L, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000;14(11):1390–9.PubMedPubMedCentral Malynn BA, de Alboran IM, O’Hagan RC, Bronson R, Davidson L, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000;14(11):1390–9.PubMedPubMedCentral
25.
Zurück zum Zitat Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, et al. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog. 2011;50(6):403–11.CrossRefPubMed Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, et al. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog. 2011;50(6):403–11.CrossRefPubMed
27.
Zurück zum Zitat Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefPubMed Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefPubMed
Metadaten
Titel
Overexpression of MYCN promotes proliferation of non-small cell lung cancer
verfasst von
Kun Liu
Shuo Wang
Yifei Liu
Jun Gu
Shudong Gu
Zhen Xu
Rui Zhang
Zhiwen Wang
Huaci Ma
Yingying Chen
Lili Ji
Publikationsdatum
23.07.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 9/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5236-2

Weitere Artikel der Ausgabe 9/2016

Tumor Biology 9/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.